- Home
- MMU vs CTNM Comparison
MMU vs CTNM Comparison
Compare MMU & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMU
- CTNM
- Stock Information
- Founded
- MMU 1992
- CTNM 2009
- Country
- MMU United States
- CTNM United States
- Employees
- MMU N/A
- CTNM N/A
- Industry
- MMU Investment Managers
- CTNM
- Sector
- MMU Finance
- CTNM
- Exchange
- MMU Nasdaq
- CTNM Nasdaq
- Market Cap
- MMU 562.0M
- CTNM 453.0M
- IPO Year
- MMU N/A
- CTNM 2024
- Fundamental
- Price
- MMU $10.43
- CTNM $14.34
- Analyst Decision
- MMU
- CTNM Strong Buy
- Analyst Count
- MMU 0
- CTNM 4
- Target Price
- MMU N/A
- CTNM $29.25
- AVG Volume (30 Days)
- MMU 170.7K
- CTNM 78.5K
- Earning Date
- MMU 01-01-0001
- CTNM 11-06-2024
- Dividend Yield
- MMU 4.92%
- CTNM N/A
- EPS Growth
- MMU N/A
- CTNM N/A
- EPS
- MMU N/A
- CTNM N/A
- Revenue
- MMU N/A
- CTNM N/A
- Revenue This Year
- MMU N/A
- CTNM N/A
- Revenue Next Year
- MMU N/A
- CTNM N/A
- P/E Ratio
- MMU N/A
- CTNM N/A
- Revenue Growth
- MMU N/A
- CTNM N/A
- 52 Week Low
- MMU $8.60
- CTNM $12.33
- 52 Week High
- MMU $10.45
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- MMU 44.83
- CTNM N/A
- Support Level
- MMU $10.31
- CTNM N/A
- Resistance Level
- MMU $10.46
- CTNM N/A
- Average True Range (ATR)
- MMU 0.08
- CTNM 0.00
- MACD
- MMU 0.02
- CTNM 0.00
- Stochastic Oscillator
- MMU 46.15
- CTNM 0.00
About MMU Western Asset Managed Municipals Fund Inc.
Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. It predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations). Under normal market conditions, a majority of its total assets are invested in municipal obligations rated investment grade at the time of investment.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.